en
Feedback
๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Open in Telegram

ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2bot

Show more

๐Ÿ“ˆ Analytical overview of Telegram channel ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Channel ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ (@aronstudy) in the Arabic language segment is an active participant. Currently, the community unites 13 329 subscribers, ranking 1 928 in the Medicine category and 5 694 in the Saudi Arabia region.

๐Ÿ“Š Audience metrics and dynamics

Since its creation on ะฝะตะฒั–ะดะพะผะพ, the project has demonstrated rapid growth, gathering an audience of 13 329 subscribers.

According to the latest data from 29 June, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by 168 over the last 30 days and by -26 over the last 24 hours, overall reach remains high.

  • Verification status: Not verified
  • Engagement rate (ER): The average audience engagement rate is 28.47%. Within the first 24 hours after publication, content typically collects 9.84% reactions from the total number of subscribers.
  • Post reach: On average, each post receives 3 795 views. Within the first day, a publication typically gains 1 312 views.
  • Reactions and interaction: The audience actively supports content: the average number of reactions per post is 37.
  • Thematic interests: Content is focused on key topics such as ู…ูŽุงุฏูŽู‘ุฉ, ุทูŽุงู„ูุจ, ุงูุณุชูุจููŠูŽุงู†, ุณูŽู„ูŽุงู…, ุฑูุณูŽุงู„ูŽุฉ.

๐Ÿ“ Description and content policy

The author describes the resource as a platform for expressing subjective opinions:
โ€œุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2botโ€

Thanks to the high frequency of updates (latest data received on 30 June, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Medicine category.

13 329
Subscribers
-2624 hours
+2647 days
+16830 days
Posts Archive
Leukemia โž” Therapy โž” Remission โž” Relapse ๐Ÿ”„
Leukemia โž” Therapy โž” Remission โž” Relapse ๐Ÿ”„

Relapse ALL Chemotherapy Allogeneic hematopoietic stem cell transplant (allo-HSCT)
Chemotherapy: ๐Ÿ”ธClofarabine โž” active in refractory acute leukemias ๐Ÿ”นBlinatumomab โž” targets CD19, for Ph negative relapsed or refractory ALL ๐Ÿ”ธInotuzumab ozogamicin โž” anti CD-22, used in relapsed and refractory B-ALL ๐Ÿ”นTisagenlecleucel โž” anti-CD19, used in patients with relapsed and refractory B-cell ALL
#Leukemia ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Treatment of ALL 5 elements: Induction CNS directed Treatment Consolidation Reinduction Maintenance phase 1. Induction Therap
Treatment of ALL
5 elements: Induction CNS directed Treatment Consolidation Reinduction Maintenance phase
1. Induction Therapy: vincristine L- asparaginase steroid (prednisone or dexamethasone) ุงู„ Dexamethazone ู‡ูˆ ุงู„ู…ูุถู„ ู„ุงู† ูŠูƒุฏุฑ ูŠูˆุตู„ ู„ู„ CNS ู…ู…ฺฉู† ุจุงู„ู€ higher risk patient ู†ุถูŠู ุฏูˆุงุก ู…ู† ู…ุฌู…ูˆุนุฉ anthracycline
2. CNS prophylaxis: A. Intrathecal: Cytarabine MTX Steroid B. Systemic chemotherapy: Dexamethasone high-dose methotrexate ุจุงู„ุงุถุงูุฉ ุงู„ู‰ ุงู„ุฃุดุนุงุน craniospinal irradiation (XRT) in selected high-risk patients (T-cell ALL)
3. Consolidation High dose of chemotherapy 4. Reinduction A. Interim maintenance 2 months B. Delayed intensification for 3 months after remission ู†ูุณ ุงุฏูˆูŠุฉ ุงู„ induction ู†ุนูŠุฏู‡ุง ู…ู† ุฌุฏูŠุฏ 5. Maintenance phase oral methotrexate 6- mercaptopurine. 2-3 years with low dose
#Leukemia ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

ุตูˆุฑ ู…ุณุชุฎุฏู…ุฉ ููŠ ุงู„ุดุฑุญ
+1
ุตูˆุฑ ู…ุณุชุฎุฏู…ุฉ ููŠ ุงู„ุดุฑุญ

https://docs.google.com/forms/d/e/1FAIpQLSeV5Ee9LB-3h0xZcBA7hqOll-OlhqGlRzwDcwH5weT2mysiqA/viewform?usp=header ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุงุญู†ุง ู…ุฌู…ูˆุนุฉ ู…ู† ุทู„ุงุจ ู…ุฑุญู„ุฉ ุฎุงู…ุณู‡ ู…ู…ูƒู† ุชุณุงุนุฏูˆู†ู‡ ูˆุชู…ู„ูˆู† ุงู„ุงุณุชุจูŠุงู† ุจุฎุตูˆุต ุงู„ุฌุฑุนู‡ ุงู„ุณุงู…ู‡ ู„ู„ุจุฑุงุณูŠุชุงู…ูˆู„ (ูู‚ุท ุทู„ุงุจ ุงู„ุฎุงู…ุณ ูˆุงู„ุฎุฑูŠุฌูŠู†)

ู…ู…ูƒู† ู†ุดุฑ ู„ู‡ุฐ ุงู„ุงุณุชุจูŠุงู† ู…ุญุชุงุฌูŠู† ุนุฏุฏ ูƒุจูŠุฑ ๐Ÿ™ https://docs.google.com/forms/d/e/1FAIpQLScqN5unW538cop6DUFvF9oUiiU_ODA2rpwItFTWaP4iIx1DtQ/viewform?usp=publish-editor

ูˆู‡ุฐู†ูŠ ูู‚ุท ู…ุญุฐูˆูุงุช ู…ู† thyroid gland ู„ุงู† ู‡ู… ู…ู† ุดุฑุญุชู‡ุง ุฌุงู† ุงู„ู…ู†ู‡ุฌ ุงู„ุฌุฏูŠุฏ ุจุนุฏู‡ ู…ุง ู†ุงุฒู„ ุนู…ูˆู…ุง ู…ูˆ ุดูŠ ู…ุคุซุฑ ุจุณ ุญุชู‰ ูŠูƒูˆู† ุจุนู„ู…ูƒู… ุจุงู‚ูŠ ุง
+1
ูˆู‡ุฐู†ูŠ ูู‚ุท ู…ุญุฐูˆูุงุช ู…ู† thyroid gland ู„ุงู† ู‡ู… ู…ู† ุดุฑุญุชู‡ุง ุฌุงู† ุงู„ู…ู†ู‡ุฌ ุงู„ุฌุฏูŠุฏ ุจุนุฏู‡ ู…ุง ู†ุงุฒู„ ุนู…ูˆู…ุง ู…ูˆ ุดูŠ ู…ุคุซุฑ ุจุณ ุญุชู‰ ูŠูƒูˆู† ุจุนู„ู…ูƒู… ุจุงู‚ูŠ ุงู„ู…ูˆุงุถูŠุน ุงุฐุง ู†ุฒู„ุช ุงู„ู‡ุง ู…ู„ุงุฒู… ู…ุฑุชุจุฉ ุฑุญ ุชูƒูˆู† ู…ุนุชู…ุฏุฉ ุน ู…ู†ู‡ุฌ ูขู ูขูฆ ู…ู† ู…ูˆุถูˆุน ุงู„ูƒุงู†ุณุฑ ูˆุตุงุนุฏ

ุทู„ุงุจ ุงู„ุฎุงู…ุณ ู…ู† ุดุฑุญุช ู…ูˆุถูˆุน ุงู„ adrenal gland ุดุฑุญุชู‡ ุน ู…ู†ู‡ุฌ ุงู„ุนุงู… ู‚ุจู„ ู„ุง ูŠู†ุฒู„ ุงู„ู…ู†ู‡ุฌ ุงู„ุฌุฏูŠุฏ ู ู‡ุงูŠ ุงู„ู…ุนู„ูˆู…ุงุช ู…ุญุฐูˆูุฉ ู…ู† ุงู„ู…ู†ู‡ุฌ ุงู„ุฌุฏ
+4
ุทู„ุงุจ ุงู„ุฎุงู…ุณ ู…ู† ุดุฑุญุช ู…ูˆุถูˆุน ุงู„ adrenal gland ุดุฑุญุชู‡ ุน ู…ู†ู‡ุฌ ุงู„ุนุงู… ู‚ุจู„ ู„ุง ูŠู†ุฒู„ ุงู„ู…ู†ู‡ุฌ ุงู„ุฌุฏูŠุฏ ู ู‡ุงูŠ ุงู„ู…ุนู„ูˆู…ุงุช ู…ุญุฐูˆูุฉ ู…ู† ุงู„ู…ู†ู‡ุฌ ุงู„ุฌุฏูŠุฏ ุชุฌุงูˆุฒูˆู‡ุง ุจุงู„ุดุฑุญ

ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุจู„ุง ุฒุญู…ุฉ ู…ู…ูƒู† ุชู†ุดุฑู„ู†ุง ู‡ุฐุง ุงู„ุฅุณุชุจูŠุงู† ุจู‚ู†ุงุชูƒู… ูƒู„ุด ู…ุญุชุงุฌูŠู† ุนูŠู†ุงุช ู ูŠุง ุฑูŠุช ุชุณุงุนุฏูˆู†ุง ุŒ ูˆ ุงู„ู„ู‡ ูŠุฌุนู„ู‡ุง ุจู…ูŠุฒุงู† ุญุณู†ุงุชูƒู… ุฌู…ูŠุนุงู‹ https://forms.gle/MC4K1X7HsvxCE6RW8

ู‚ู†ุงุฉ ุฏูƒุชูˆุฑ ุนุจุงุณ ุงู† ุดุงุก ุงู„ู„ู‡ ุชููŠุฏูƒู… ุงู„ุงุฏูุงู†ุณ

๐Ÿ›‘ู‚ู†ุงุฉ ุฎุงุตุฉ ุจุดุฑุญ ู…ุงุฏุฉ ุงู„ุฃุฏูุงู†ุณ ู„ู„ู…ุฑุญู„ุฉ5 ูƒู„ูŠุฉ ุงู„ุตูŠุฏู„ุฉ ุจุงู„ุฅุนุชู…ุงุฏ ุนู„ู‰ ุงู„ู…ุตุฏุฑ ุงู„ูˆุฒุงุฑูŠ ู„ุณู†ุฉ 2026โœ… ๐Ÿ›‘ุดุฑุญ ุงู„ุตูŠุฏู„ุงู†ูŠ ุนุจุงุณ ุญูŠุฏุฑ ู‡ู„ุงู„โœ… ุฎุฑูŠุฌ ูƒู„ูŠุฉ ุงู„ุตูŠุฏู„ุฉ(ุฌุงู…ุนุฉ ุงู„ู‚ุงุฏุณูŠุฉ) ู…ู† ุงู„ุฃูˆุงุฆู„ ุนู„ู‰ ุงู„ูƒู„ูŠุฉโœ… ๐Ÿ›‘ุงู„ุดุฑุญ ุนู„ู‰ ุงู„ู…ุตุฏุฑ ุงู„ูˆุฒุงุฑูŠ ุงู„ู…ูˆุญุฏ ูˆุนู„ู‰ ุดูƒู„ ูุฏูŠูˆุงุช ุจุงู„ูŠูˆุชูŠูˆุจ+ ุญู„ ุฃุณุฃู„ุฉ ูˆู…ู„ุฎุตุงุช ุจู‚ู†ุงุฉ ุงู„ุชู„ูŠโœ… ๐Ÿ›‘ุฑุงุจุท ุงู„ู‚ู†ุงุฉ ุจุงู„ุชู„ูŠ/ t.me/Ph_Abbas_Hilal โœ… ๐Ÿ›‘ู…ุนุฑู ุงู„ุชู„ูŠ/ @ph6ab โœ… ๐Ÿ›‘ุฑุงุจุท ุดุฑุญ ุฃูˆู„ ูุฏูŠูˆ ุนู„ู‰ ุงู„ูŠูˆุชูŠูˆุจ/ https://youtu.be/BLwWJx2vZqc?si=p7KNoOqQtvLAE4o3 โœ